Gene Test Determines Risk of Heart Surgery Complications
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Gene Test Determines Risk of Heart Surgery Complications

WASHINGTON, DC -- April 30, 2009 -- Genetic differences can explain why some patients undergoing heart surgery later experience shock and kidney complications, according to a study appearing in the online April 30 issue of the Journal of the American Society Nephrology.

The results indicate that performing a genetic test on patients before they have surgery can help guide treatment after they leave the operating room.

While cardiac surgery puts an individual at risk for developing shock and kidney failure, there are no effective medications to prevent these complications. When shock occurs, patients are often given norepinephrine to stimulate their blood vessels and normalise their blood pressure.

Unfortunately, people respond differently to norepinephrine -- some metabolise it efficiently, while others do not. The likely reason for these differences lies within biological pathways that metabolise norepinephrine and involve the enzyme catechol-O-methyltransferase (COMT).

Duska Dragun, MD and Anja Haase-Fielitz, PhD, Charité Universitätsmedizin, Berlin, Germany, and colleagues studied the gene that encodes COMT in 260 patients who underwent heart bypass surgery.

They found that a particular genetic variant in some individuals can lead to lower activity of the COMT enzyme, which makes them less responsive to norepinephrine's effects. People who had this variant (called LL) were more likely to develop shock and kidney failure, requiring a hospital stay for a longer period of time.

The link between the COMT LL variant and these complications may be pronounced in women because protective oestrogen metabolites can be inactivated by norepinephrine. Additional studies are needed to test this hypothesis.

If this study's results are confirmed in larger clinical trials, physicians could use a COMT gene test to help them determine a patient's risk of developing complications following cardiac surgery and could therefore help them prepare for their patient's post-surgery care.

SOURCE: American Society of Nephrology

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities